PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Propranolol

Drugs in development · updated 30 October 2026

Propranolol: clinical trials and development status

Other names and codes: Hemangeol, Innopran Xl, Inderal

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 23 April 2014

As of 30 October 2026 Propranolol is in 43 active clinical trials (recruiting or ongoing, phases I–III) for 55 diseases. The most advanced phase is III.

43Active trials
IIIMost advanced phase
55Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Propranolol and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 55 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Traumatic brain injuryIII3NCT07899164
Post-traumatic stress disorderIII2NCT07792122
Capillary hemangiomaII–III1NCT06798363
MigraineIII1NCT07147972
UlcerII–III1NCT06798363
Non-small-cell lung carcinomaII3NCT06120140
Esophagus adenocarcinomaII2NCT04682158
Kaposi's sarcomaII2NCT05797662
MelanomaII2NCT07836712
Ovarian neoplasmII2NCT07125391
Pancreatic neoplasmII2NCT05451043
Postural orthostatic tachycardia syndromeI–II2NCT00262470
SarcomaII2NCT06445166
TachycardiaI–II2NCT00262470
AggressionII1NCT07091279
Autism spectrum disorderII1NCT07091279
Autistic DisorderII1NCT07091279
Biliary tract neoplasmII1NCT05451043
Bladder neoplasmII1NCT04848519
CholangiocarcinomaII1NCT05451043
Colonic neoplasmII1NCT07549906
Colorectal neoplasmII1NCT03919461
Combat disorderII1NCT07452978
Digestive system neoplasmII1NCT06775080
HemangiosarcomaII1NCT05961761
Hepatocellular carcinomaII1NCT07836712
Histiocytoma, Malignant FibrousII1NCT05961761
Liver neoplasmII1NCT05451043
NeoplasmII1NCT06839144
Problem behaviorII1NCT07091279

Everything on Propranolol

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch